Peer Revolution Medicines' positive Phase 3 RAS inhibitor data sparks sympathy surge for ERAS in premarket.
Revolution Medicines (RVMD) reported strong Phase 3 overall survival benefits for its RAS(ON) multi-selective inhibitor daraxonrasib in metastatic pancreatic cancer, a major validation for RAS/MAPK pathway targeting in oncology. Erasca, focused on its pan-RAS molecular glue ERAS-0015 (with encouraging early dose-escalation responses across RAS-mutant tumors announced in January 2026 and additional Phase 1 data expected in H1 2026), rose sharply in sympathy during premarket trading on April 13. This move builds on ERAS’s existing momentum—over 300% YTD gains fueled by its own clinical progress, a strengthened balance sheet from a January 2026 financing, worldwide licensing for ERAS-0015, collaborations (e.g., with Tango Therapeutics), and multiple analyst price target hikes (HC Wainwright to $20, Mizuho to $19, JPMorgan to $25). Retail and sector rotation interest amplified the move as traders positioned around upcoming RAS-focused readouts. The stock broke toward or past recent highs near $18–19 amid elevated premarket volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.